ESMO: GSK’s Zejula misses survival goal in first-line ovarian cancer, as Pharma&’s combo disappoints aliu Fri, 09/13/2024 – 17:00 More: ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as Pharma&'s combo disappoints Source: fierce
read moreESMO: Merck unpacks a mixed bag of gynecological cancer results for Keytruda zbecker Fri, 09/13/2024 – 16:57 More: ESMO: Merck unpacks a mixed bag of gynecological cancer results for Keytruda Source: fierce
read moreRoche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus kdunleavy Fri, 09/13/2024 – 13:23 More: Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus Source: fierce
read moreESMO: AZ, Daiichi build case for Enhertu in breast cancer patients with brain metastases fkansteiner Fri, 09/13/2024 – 11:07 More: ESMO: AZ, Daiichi build case for Enhertu in breast cancer patients with brain metastases Source: fierce
read moreAfter delay, Roche’s Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug zbecker Fri, 09/13/2024 – 11:06 More: After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug Source: fierce
read moreESMO: AstraZeneca stands by Truqap despite surprise breast cancer flop aliu Fri, 09/13/2024 – 09:30 More: ESMO: AstraZeneca stands by Truqap despite surprise breast cancer flop Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals